ReNeuron’s interim results highlight the progress of its stem cell therapy candidates with data from its CTX stem cell therapy candidate for stroke (Phase II), critical limb ischaemia (Phase I) and hRPC stem cell therapy candidate for retinitis pigmentosa (Phase I/II) due in 2016. We continue to view ReNeuron as a key player in the stem cell therapy field and look forward to the news flow over the next twelve months. We remain at Buy and view the current share price as an attractive entry point ....
07 Dec 2015
Interim results: 2016 an important year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interim results: 2016 an important year
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
07 Dec 2015 -
Author:
Sheena Berry -
Pages:
3
ReNeuron’s interim results highlight the progress of its stem cell therapy candidates with data from its CTX stem cell therapy candidate for stroke (Phase II), critical limb ischaemia (Phase I) and hRPC stem cell therapy candidate for retinitis pigmentosa (Phase I/II) due in 2016. We continue to view ReNeuron as a key player in the stem cell therapy field and look forward to the news flow over the next twelve months. We remain at Buy and view the current share price as an attractive entry point ....